Fact CheckerSign in

NCT07429851Recruiting

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

CLINical, Pathological and outcomE compArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors: a Retrospective Observational Study

Source: ClinicalTrials.gov · Last updated 24 Feb 2026

Brief summary (registry, in English)

The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes, imaging, disease evolution and molecular profiling. This study will adopt a hypothesis-generating approach to explore whether patients in these distinct groups differ clinically in terms of diagnosis and treatment management.

Status (registry)
Recruiting
Study type
Observational
Enrollment
34 (estimated)
First submitted
5 Feb 2026
Start date
1 Jan 2026
Primary completion date
31 Mar 2026
Lead sponsor
European Institute of Oncology
NCT number
NCT07429851

What you commit to

  • Study type: Observational
  • Planned participants: 34
  • From 1 Jan 2026 to the primary completion date, 31 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 \< 20%.
  • Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs)
  • Inadequate or unavailable tumor tissue for molecular analysis.
  • Incomplete clinical records or follow-up.
  • Other primary sites, except lung or pancreas.

Who the study is looking for

  • Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist.
  • Primary tumor site:thyme, lung and duodenum-pancreas NETs.
  • Advanced stage of tumor disease and Any number of lines of therapy
  • Sufficient available clinical data on diagnosis, treatments, outcomes.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
European Institute of Oncology
Coordinator of this site? Confirm its status
MilanItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.